Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: There is growing interest in investigating the adenosine-dopamine interaction in the ventral striatum. Adenosine plays a role opposite to dopamine in the striatum and adenosine antagonists, like caffeine, produce similar effects to increased dopaminergic neurotransmission in the striatum. In particular, a strong antagonistic interaction between adenosine A2A and dopamine D2 receptors takes place in the striopallidal GABAergic neurones. Therefore, adenosine agonists or uptake inhibitors provide a potential new treatment for schizophrenia. We undertook a pilot trial to investigate whether the combination of haloperidol with dipyridamole, an uptake inhibitor of adenosine, was more effective than haloperidol alone. METHODS: Thirty patients who met the DSM IV criteria for schizophrenia completed the study. Patients were allocated in a random fashion, 16 to haloperidol 20 mg/day plus dipyridamole 75 mg/day and 14 to haloperidol 20 mg/day plus placebo. RESULTS: Although both protocols significantly decreased the score of the positive, negative and general psychopathological symptoms over the trial period, the combination of haloperidol and dipyridamole was significantly better than haloperidol alone in decreasing positive and general psychopathology symptoms as well as PANSS total scores. CONCLUSION: Dipyridamole may be of therapeutic benefit in treating schizophrenia in combination with neuroleptics. However, a larger study to confirm our results is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Genetics of Schizophrenia: A Current, Genetic-epidemiologic Perspective
Kendler, K. S., & Diehl, S. R. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.2.261 · Cited by 568
Angrist, B., Rotrosen, J., & Gershon, S. (1980) · Psychopharmacology · doi:10.1007/bf00433802 · Cited by 344
Cited by
Ribeiro, J. A., & Sebastião, A. M. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1379 · Cited by 577
Adenosine receptors in the nervous system: pathophysiological implications
Ribeiro, J. A., Sebastião, A. M., & de Mendonça, A. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00155-7 · Cited by 509
Hillion, J., Canals, M., Torvinen, M., Casadó, V., Scott, R., Terasmaa, A., Hansson, A., Watson, S., Olah, M. E., Mallol, J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107731200 · Cited by 500
Adenosine receptors and brain diseases: neuroprotection and neurodegeneration
Gomes, C. V., Kaster, M. P., Tomé, A. R., Agostinho, P. M., & Cunha, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.001 · Cited by 419
“Evidence of altered adenosinergic activity in schizophrenia includes the upregulation of striatal A2AR [348], which could be compensatory to low adenosinergic activity [340], as well as the clinical improvement of schizophrenic patients with dipyridamole and allopurinol, two pharmacological agents enhancing adenosine…”
BackgroundPurinergic signalling: From normal behaviour to pathological brain function
Burnstock, G., Krügel, U., Abbracchio, M. P., & Illes, P. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.006 · Cited by 397
Metadata
- Authors
- Akhondzadeh, Shasavand, Jamilian, Shabestari, & Kamalipour
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2000-04
- Volume
- 25
- Issue
- 2
- Pages
- 131-137
- ISSN
- 0269-4727 (ISSN-L)
- 1365-2710
- OpenAlex
- W2092051242
- Cited by
- 106
- References
- 2
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. https://app.cochat.ai/papers/10.1046/j.1365-2710.2000.00273.x
- The paper
- Akhondzadeh, Shasavand, Jamilian, Shabestari, & Kamalipour. (2000). Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. Journal of Clinical Pharmacy and Therapeutics. https://doi.org/10.1046/j.1365-2710.2000.00273.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.